These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 23482788)

  • 41. Double-staining Immunohistochemistry Reveals in Malignant Pleural Mesothelioma the Coexpression of ERCC1 and RRM1 as a Frequent Biological Event Related to Poorer Survival.
    Zito Marino F; Baselice S; Erra S; Ronchi A; Montella M; Morgillo F; Vicidomini G; Santini M; Poziello G; Cozzolino I; Accardo M; Franco R
    Appl Immunohistochem Mol Morphol; 2021 Mar; 29(3):231-238. PubMed ID: 32842027
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Differences in the expression profiles of excision repair crosscomplementation group 1, x-ray repair crosscomplementation group 1, and betaIII-tubulin between primary non-small cell lung cancer and metastatic lymph nodes and the significance in mid-term survival.
    Kang CH; Jang BG; Kim DW; Chung DH; Kim YT; Jheon S; Sung SW; Kim JH
    J Thorac Oncol; 2009 Nov; 4(11):1307-12. PubMed ID: 19745766
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer.
    Koh Y; Jang B; Han SW; Kim TM; Oh DY; Lee SH; Kang CH; Kim DW; Im SA; Chung DH; Kim YT; Kim TY; Kim YW; Kim JH; Heo DS; Bang YJ
    J Thorac Oncol; 2010 Mar; 5(3):320-5. PubMed ID: 20087230
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
    Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T
    Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prognostic impact of cancer stem cell-related markers in non-small cell lung cancer patients treated with induction chemoradiotherapy.
    Shien K; Toyooka S; Ichimura K; Soh J; Furukawa M; Maki Y; Muraoka T; Tanaka N; Ueno T; Asano H; Tsukuda K; Yamane M; Oto T; Kiura K; Miyoshi S
    Lung Cancer; 2012 Jul; 77(1):162-7. PubMed ID: 22387005
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Low expression of excision repair cross-complementation group-1 protein predicts better outcome in patients with locally advanced nasopharyngeal cancer treated with concurrent chemoradiotherapy.
    Zhang Z; Jiang C; Hu L
    Tumori; 2014; 100(3):328-32. PubMed ID: 25076246
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Excision repair cross complementing-1 and topoisomerase IIalpha gene expression in small-cell lung cancer patients treated with platinum and etoposide: a retrospective study.
    Ceppi P; Longo M; Volante M; Novello S; Cappia S; Bacillo E; Selvaggi G; Saviozzi S; Calogero R; Papotti M; Scagliotti GV
    J Thorac Oncol; 2008 Jun; 3(6):583-9. PubMed ID: 18520795
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [ERCC1 and TS expression in chemoradiotherapy treated esophageal squamous cell carcinoma].
    Sobajima J; Haga N; Kumamoto K; Ishibashi K; Ishida H
    Gan To Kagaku Ryoho; 2010 Nov; 37(12):2394-6. PubMed ID: 21224584
    [TBL] [Abstract][Full Text] [Related]  

  • 49. ERCC1 and RRM1: ready for prime time?
    Besse B; Olaussen KA; Soria JC
    J Clin Oncol; 2013 Mar; 31(8):1050-60. PubMed ID: 23401439
    [TBL] [Abstract][Full Text] [Related]  

  • 50. ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy.
    Hwang IG; Ahn MJ; Park BB; Ahn YC; Han J; Lee S; Kim J; Shim YM; Ahn JS; Park K
    Cancer; 2008 Sep; 113(6):1379-86. PubMed ID: 18623378
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
    Li Z; Qing Y; Guan W; Li M; Peng Y; Zhang S; Xiong Y; Wang D
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):777-86. PubMed ID: 25107571
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Biomarkers - the way towards individualized chemotherapy in non-small cell lung cancer (NSCLC)].
    Danzinger S; Filipits M
    Wien Med Wochenschr; 2007; 157(21-22):554-61. PubMed ID: 18157593
    [TBL] [Abstract][Full Text] [Related]  

  • 53. ERCC1 expression does not predict survival and treatment response in advanced stage non-small cell lung cancer cases treated with platinum based chemotherapy.
    Ozdemir O; Ozdemir P; Veral A; Uluer H; Ozhan MH
    Asian Pac J Cancer Prev; 2013; 14(8):4679-83. PubMed ID: 24083725
    [TBL] [Abstract][Full Text] [Related]  

  • 54. PSF1 (Partner of SLD Five 1) is a Prognostic Biomarker in Patients with Non-small Cell Lung Cancer Treated with Surgery Following Preoperative Chemotherapy or Chemoradiotherapy.
    Kanzaki R; Naito H; Kise K; Takara K; Eino D; Minami M; Shintani Y; Funaki S; Kawamura T; Kimura T; Okumura M; Takakura N
    Ann Surg Oncol; 2016 Nov; 23(12):4093-4100. PubMed ID: 27380644
    [TBL] [Abstract][Full Text] [Related]  

  • 55. X-ray cross-complementing group 1 and thymidylate synthase polymorphisms might predict response to chemoradiotherapy in rectal cancer patients.
    Lamas MJ; Duran G; Gomez A; Balboa E; Anido U; Bernardez B; Rana-Diez P; Lopez R; Carracedo A; Barros F
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):138-44. PubMed ID: 21167658
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Expression of TS, RRM1, ERCC1, TUBB3 and STMN1 Genes in Tissues of Non-small Cell Lung Cancer and its Significance in Guiding Postoperative Adjuvant Chemotherapy.
    Zou ZQ; Du YY; Sui G; Xu SN
    Asian Pac J Cancer Prev; 2015; 16(8):3189-94. PubMed ID: 25921119
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Expression of ERCC1 and BRCA1 predict the clinical outcome of non-small cell lung cancer in patients receiving platinum-based chemotherapy.
    Wang TB; Zhang NL; Wang SH; Li HY; Chen SW; Zheng YG
    Genet Mol Res; 2014 May; 13(2):3704-10. PubMed ID: 24854656
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intratumour variation of biomarker expression by immunohistochemistry in resectable non-small cell lung cancer.
    Jakobsen JN; Santoni-Rugiu E; Ravn J; Sørensen JB
    Eur J Cancer; 2013 Jul; 49(11):2494-503. PubMed ID: 23639410
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Features of potentially predictive biomarkers of chemotherapeutic efficacy in small cell lung cancer.
    Chiappori AA; Zheng Z; Chen T; Rawal B; Schell MJ; Mullaney BP; Bepler G
    J Thorac Oncol; 2010 Apr; 5(4):484-90. PubMed ID: 20107425
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Expression of ribonucleoside reductase subunit M1, but not excision repair cross-complementation group 1, is predictive in muscle-invasive bladder cancer treated with chemotherapy and radiation.
    Shilkrut M; Wu A; Thomas DG; Hamstra DA
    Mol Clin Oncol; 2014 May; 2(3):479-487. PubMed ID: 24772321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.